Your session is about to expire
← Back to Search
Cancer Vaccine
STAVs + Dendritic Cell Vaccine for Aggressive Relapsed/Refractory Leukemias
Phase 1
Waitlist Available
Led By Juan C Ramos, MD
Research Sponsored by Juan C. Ramos, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial is investigating whether a combination of STING-dependent Adjuvants and dendritic cell vaccine therapies can help the body fight aggressive leukemias that have come back or haven't responded to treatment.
Eligible Conditions
- Leukemia
- Adult T-Cell Leukemia/Lymphoma
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of Treatment-Related Adverse events
Secondary outcome measures
Failure-free survival (FFS) rate
Overall survival (OS)
Percentage of Participants Achieving Clinical Complete Response (CR)
+4 moreSide effects data
From 2013 Phase 2 trial • 11 Patients • NCT0032311510%
Pain, neck, unilateral, Grade 2
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vaccine
Trial Design
1Treatment groups
Experimental Treatment
Group I: Combination STAVs and DC Vaccine GroupExperimental Treatment2 Interventions
Participants will receive STAV-loaded cells for a total of 5 doses on Days 3, 17, 31, 45 and 59. Participants will also receive up to 4 doses of dendritic vaccine on Days 10, 17, 24 and 31.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dendritic Cell Vaccine
2011
Completed Phase 2
~140
Find a Location
Who is running the clinical trial?
Juan C. Ramos, MDLead Sponsor
Juan C Ramos, MDPrincipal InvestigatorUniversity of Miami
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying Leukemia
10 Patients Enrolled for Leukemia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have tried standard chemotherapy treatments without success and are not able to receive a stem cell transplant. For ATLL, you have not responded to specific chemotherapy treatments or antibody therapy, and your doctor has determined that you are not eligible for these treatments.
Research Study Groups:
This trial has the following groups:- Group 1: Combination STAVs and DC Vaccine Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this research actively looking for participants?
"This clinical trial is not actively searching for participants, despite having been initially posted on January 1st 2023 and last updated November 14th 2022. Nevertheless, there are more than 1600 other medical studies currently recruiting patients."
Answered by AI
How does Dendritic Cell Vaccine impact patients' wellbeing?
"Our team at Power gave Dendritic Cell Vaccine a score of 1 due to the limited clinical evidence backing its safety and efficacy, since it is currently in Phase 1."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger